Taurolidine is an antibacterial and antifungal agent with a mechanism of action that is less prone to development of antimicrobial resistance. A taurolidine/heparin lock solution carries a lower risk ...

This is the first FDA-approved antimicrobial catheter lock solution. The FDA has approved taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections ...

The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...

DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...

The effectiveness of various solutions instilled into the central venous catheter lumens after each hemodialysis session (catheter locking solutions) to decrease the risk of catheter malfunction and ...

The FDA approved a taurolidine and heparin (DefenCath) catheter lock solution for reducing the risk of bloodstream infections in patients on dialysis. Approved under a special limited agency pathway, ...